NCT01084005 - Efficacy and Safety of Linagliptin in Elderly Patients With Type 2 Diabetes | Biotech Hunter

Enrollment

241

Participants

Timeline

Start Date

March 31, 2010

Primary Completion Date

June 30, 2011

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG

linagliptin

patients receive linagliptin 5 mg tablets once daily

DRUG

placebo

patients receive placebo matching linagliptin 5 mg once daily

Trial Locations (34)

Unknown

1218.63.61005 Boehringer Ingelheim Investigational Site, Gosford

1218.63.61006 Boehringer Ingelheim Investigational Site, Herston

1218.63.61003 Boehringer Ingelheim Investigational Site, Adelaide

1218.63.61002 Boehringer Ingelheim Investigational Site, Daw Park

1218.63.61007 Boehringer Ingelheim Investigational Site, East Ringwood

1218.63.61001 Boehringer Ingelheim Investigational Site, Parkville

1218.63.61004 Boehringer Ingelheim Investigational Site, Reservoir

1218.63.10008 Boehringer Ingelheim Investigational Site, Vancouver

1218.63.10003 Boehringer Ingelheim Investigational Site, Hamilton

1218.63.10005 Boehringer Ingelheim Investigational Site, Hawkesbury

1218.63.10007 Boehringer Ingelheim Investigational Site, Newmarket

1218.63.10006 Boehringer Ingelheim Investigational Site, Toronto

1218.63.10001 Boehringer Ingelheim Investigational Site, Montreal

1218.63.10002 Boehringer Ingelheim Investigational Site, Saint Romuald

1218.63.10004 Boehringer Ingelheim Investigational Site, Saskatoon

1218.63.45007 Boehringer Ingelheim Investigational Site, Aalborg

1218.63.45002 Boehringer Ingelheim Investigational Site, Aarhus C

1218.63.45003 Boehringer Ingelheim Investigational Site, Aarhus C

1218.63.45001 Boehringer Ingelheim Investigational Site, Birkerød

1218.63.45008 Boehringer Ingelheim Investigational Site, Hellerup

1218.63.45006 Boehringer Ingelheim Investigational Site, Hillerød

1218.63.45004 Boehringer Ingelheim Investigational Site, Hvidovre

1218.63.45005 Bispebjerg Hospital, København NV

1218.63.31008 Boehringer Ingelheim Investigational Site, Beek en Donk

1218.63.31007 Boehringer Ingelheim Investigational Site, Beerzerveld

1218.63.31012 Boehringer Ingelheim Investigational Site, Doetinchem

1218.63.31014 Boehringer Ingelheim Investigational Site, Etten-Leur

1218.63.31009 Boehringer Ingelheim Investigational Site, Oude Pekela

1218.63.31001 Boehringer Ingelheim Investigational Site, Tubbergen

1218.63.46004 Boehringer Ingelheim Investigational Site, Gothenburg

1218.63.46003 Boehringer Ingelheim Investigational Site, Järfälla

1218.63.46001 Boehringer Ingelheim Investigational Site, Malmo

1218.63.46002 Boehringer Ingelheim Investigational Site, Sundsvall

1218.63.46005 Boehringer Ingelheim Investigational Site, Uppsala